Skip to main content

Table 6 Comparison between the published studies and the current study

From: Evaluation of response to conventional chemotherapy and radiotherapy by perfusion computed tomography in non-small cell lung cancer (NSCLC)

First author [reference] Number of patients Histology CCT RT Targeted therapy RECIST assessment Blood flow Blood volume Mean transit time Permeability
Wang et al [23] 35 Epidermoid Adenocarcinoma No Yes No Response
p > 0.05
Wang et al [23] 12 Epidermoid Adenocarcinoma Yes No No Response Progression
Fraioli et al [24] 45 Adenocarcinoma Yes   Bevacizumab Response   
Lind et al [25] 23 Adenocarcinoma
Epidermoid
Large cell
   Sorafenib
Erlotinib
Response    
Tacelli et al [26] 17 Adenocarcinoma Yes   Bevacizumab Response   
Tacelli et al [26] 23 Adenocarcinoma
Epidermoid
Large cell
Yes No No Response   
Sudarski et al [27] 100 Adenocarcinoma
Epidermoid
Yes No No Response Progression Stable
Sudarski et al [27] 100 Small cell Yes No No Response Progression Stable
Trinidad et al [current study] 7 Adenocarcinoma Epidermoid Large cell Yes Yes No Response
p > 0.05

p > 0.05

p > 0.05

p > 0.05
Trinidad et al [current study] 46 Adenocarcinoma Epidermoid Large cell Yes No No Response   
  1. Changes by treatment in perfusion parameters in lung cancer reported by different published studies:↑ = significant increase; ↓ = significant decrease; ↕ = in some patients, the parameter increases and in other patients, it decreases; ↔ = there were no changes; p > 0.05 nonsignificant changes
  2. RECIST Response evaluation criteria in solid tumours